Goldman Sachs notes that Vera Therapeutics (VERA) shares are down 18% and underperforming the biotech group today following earnings results ...

Goldman Sachs has initiated coverage of Vera Therapeutics (NASDAQ:VERA) with a buy rating, citing the potential of its drug candidate atacicept and a recent pullback in the stock. The investment ...

Goldman Sachs has rebounded significantly, with its stock up 116% since November 2023. The company's earnings exceeded expectations, driven by increased M&A and IPO activities. Some analysts ...

After years of bashing cryptocurrencies, US investment bank Goldman Sachs has admitted it was wrong about the asset class. Not in words, but with actions. The investment giant, which manages ...

The Goldman Sachs Group started coverage on shares of Vera Therapeutics (NASDAQ:VERA – Free Report) in a research note issued to investors on Tuesday morning, Marketbeat reports. The firm issued ...

Goldman Sachs has promoted several new executives for its major business lines, reflecting a shift in leadership, including two Indian Americans Anshul Sehgal and Kunal Shah.(Image: Pexels ...

Goldman Sachs CEO David Solomon is scrapping a key DEI policy that banned the bank from doing IPOs for companies with white, all-male boards. It marks a major U-turn for Goldman amid a White House ...

Goldman Sachs announced a leadership reshuffle this week that created a new layer of management for its all-important investment bank. As part of the reshuffle, Goldman tapped three of its most ...

Goldman Sachs CEO David Solomon pointed out that one of the many use case of AI in banking could be to help with writing financial documents. Goldman Sachs CEO David Solomon said investment banks ...

Goldman Sachs BDC's portfolio has diversified sector exposure, with notable changes in exposure to software, health care, and professional services since our last coverage. Despite an earnings ...